SCHEMBL4385392

SCHEMBL4385392

CC(=O)SC1CCN(C(c2ccccc2)(c2ccccc2)c2ccccc2)C/C1=C/CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31
CHRM2 P08172 3/20 0.31
CHRM3 P20309 3/20 0.31
BTN3A1 O00481 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4385395 1.00 LMNA (0.31) LMNACHRM2CHRM3BTN3A1
SCHEMBL4385390 1.00 LMNA (0.31) LMNACHRM2CHRM3BTN3A1
SCHEMBL4389289 0.89 SMYD2 (0.33) CHRM2CHRM3
SCHEMBL4389296 0.89 SMYD2 (0.33) CHRM2CHRM3
SCHEMBL4389293 0.89 SMYD2 (0.33) CHRM2CHRM3
SCHEMBL4396881 0.83 CHRM3 (0.32) CHRM2CHRM3
SCHEMBL4389060 0.83 CHRM3 (0.32) CHRM2CHRM3
SCHEMBL4386025 0.83 CHRM3 (0.32) CHRM2CHRM3
SCHEMBL4386023 0.83 CHRM3 (0.32) CHRM2CHRM3
SCHEMBL4396877 0.83 CHRM3 (0.32) CHRM2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306059-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-10 US disclosed
EP-1889835-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP Daiichi Sankyo Company, Limited (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306059-A1 CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP CBR3, CNR1, C3AR1 LMNA 1421/4885CHRM2 13/4885CHRM3 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.